2-((6-(bromomethyl)pyridin-2-yl)methyl)isoindoline-1,3-dione | 192379-53-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-((6-(bromomethyl)pyridin-2-yl)methyl)isoindoline-1,3-dione
• 英文别名: 2-[[6-(Bromomethyl)pyridin-2-yl]methyl]isoindole-1,3-dione
• CAS: 192379-53-6
• 化学式: C₁₅H₁₁BrN₂O₂
• 分子量: 331.169
• InChiKey: NFOIFTJARPIMEW-UHFFFAOYSA-N

物化性质

• 沸点：
  457.7±40.0 °C(Predicted)
• 密度：
  1.626±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  50.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-((6-(bromomethyl)pyridin-2-yl)methyl)isoindoline-1,3-dione 在 potassium carbonate 、 苯硫酚 、 肼 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 51.0h， 生成 tert-butyl N-[2-[[6-(aminomethyl)pyridin-2-yl]methylamino]ethyl]-N-(3-hydroxypropyl)carbamate
  参考文献：
  名称：

  Solution Phase Combinatorial Chemistry. Synthesis of Novel Linear Pyridinopolyamine Libraries with Potent Antibacterial Activity

  摘要：

  Novel linear pyridinopolyamine derivatives 1-3, 7, and 8 have been synthesized as scaffolds for combinatorial drug discovery. The mono-t-Boc- and monotosyl-protected linear scaffolds 1 and 2 were obtained by a Schiff base type cyclization of 2,6-pyridinedicarboxaldehyde (24) with monoprotected triamines 22 and 23 using Ni2+ as a metal template, followed by reductive cleavage and decomplexation in a one-pot procedure. The unprotected linear scaffold 3 was obtained by treating 1 with TFA, Scaffold 1 was also synthesized from the orthogonally protected pyridinopolyamine 7 which was constructed from 2,6-bis(bromomethylipyridine (29) in four steps. Selective deprotection of the key intermediate 7 afforded 8, which was further selectively deprotected to give scaffold 1. A combinatorial chemistry strategy involving solution phase simultaneous addition of functionalities (SPSAF) is described. Thirteen high-purity tertiary amine libraries 19-21) (total 1638 compounds) were synthesized by the SPSAF and fix last methodologies from linear polyamine scaffolds 1 and 2. All libraries were examined by TLC, purified by chromatographic techniques, and characterized by H-1 NMR and ESI RIS spectral data. A fur last methodology was utilized to minimize chemical reactions and perform SAR studies directly on libraries. Several first-round sublibraries of scaffold 1 containing 126 compounds each, exhibited potent antibacterial activity with MICs of 1-12 mu M against Streptococcus pyogenes and Escherichia coli imp(-).

  DOI：

  10.1021/jo970535j
• 作为产物：
  描述：

  2,6-双(溴甲基)吡啶 、 potassium phtalimide 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-((6-(bromomethyl)pyridin-2-yl)methyl)isoindoline-1,3-dione
  参考文献：
  名称：

  用于选择性锂盐识别的三（吡啶-2-基甲基）胺基离子对受体

  摘要：

  由与三个对硝基苯基脲或三个氨基硝基吲哚连接的三(吡啶-2-基)甲胺组成的三足离子对受体选择性地识别锂盐。

  DOI：

  10.1002/ejoc.202200808

文献信息

• [EN] ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES<br/>[FR] BENZOPYRAZINES ANTICANCÉREUSES PAR LE BIAIS DE L'INHIBITION DE FGFR KINASES
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2013061081A1

  公开（公告）日：2013-05-02

  The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

  这项发明涉及新的喹啉衍生物化合物，包括含有该化合物的药物组合物，用于制备该化合物的方法以及该化合物在治疗疾病（例如癌症）中的用途。
• [EN] MANGANESE-BASED MAGNETIC RESONANCE CONTRAST AGENTS<br/>[FR] AGENTS DE CONTRASTE POUR RÉSONANCE MAGNÉTIQUE À BASE DE MANGANÈSE
  申请人：GEN HOSPITAL CORP

  公开号：WO2014107722A1

  公开（公告）日：2014-07-10

  Manganese coordination complexes with utility as magnetic resonance probes and as biological reductant sensors are disclosed. In one embodiment, ligands can stabilize both the Mn2+ and Mn3+ oxidation states. In the presence of a reductant such as glutathione, low relaxivity MnIII-HBET is rapidly converted to high relaxivity MnII-HBET with a 3-fold increase in relaxivity, and concomitant increase in magnetic resonance signal. In another embodiment, ligands were designed to chelate Mn(ll) in a thermodynamically stable and kinetically inert fashion while allowing for direct interaction of Mn(ll) with water. In yet another embodiment, high molecular weight multimers containing six Mn(ll) chelators were prepared. The high molecular weight results in slower tumbling of the molecules in solution and can strongly enhance the Mn(ll) relaxivity.

  锰配位络合物具有作为磁共振探针和生物还原剂传感器的实用性。在一个实施例中，配体可以稳定Mn2+和Mn3+的氧化态。在存在谷胱甘肽等还原剂的情况下，低弛豫率的MnIII-HBET会迅速转化为高弛豫率的MnII-HBET，其弛豫率增加了3倍，并伴随着磁共振信号的增加。在另一个实施例中，设计了配体以热力学稳定和动力学惰性的方式螯合Mn(ll)，同时允许Mn(ll)与水直接相互作用。在另一个实施例中，制备了含有六个Mn(ll)螯合剂的高分子量多聚体。高分子量导致溶液中分子的翻滚速度较慢，并且可以强烈增强Mn(ll)的弛豫率。
• MANGANESE-BASED MAGNETIC RESONANCE CONTRAST AGENTS
  申请人：CARAVAN Peter

  公开号：US20150336996A1

  公开（公告）日：2015-11-26

  Manganese coordination complexes with utility as magnetic resonance probes and as biological reductant sensors are disclosed. In one embodiment, ligands can stabilize both the Mn 2+ and Mn 3+ oxidation states. In the presence of a reductant such as glutathione, low relaxivity Mn III -HBET is rapidly converted to high relaxivity Mn II -HBET with a 3-fold increase in relaxivity, and concomitant increase in magnetic resonance signal. In another embodiment, ligands were designed to chelate Mn(ll) in a thermodynamically stable and kinetically inert fashion while allowing for direct interaction of Mn(ll) with water. In yet another embodiment, high molecular weight multimers containing six Mn(ll) chelators were prepared. The high molecular weight results in slower tumbling of the molecules in solution and can strongly enhance the Mn(ll) relaxivity.

  本文介绍了具有作为磁共振探针和生物还原物传感器实用性的锰配位化合物。在一种实施方式中，配体可以稳定Mn2+和Mn3+的氧化态。在存在还原剂如谷胱甘肽的情况下，低弛豫率MnIII-HBET会迅速转化为高弛豫率MnII-HBET，弛豫率增加3倍，磁共振信号同时增加。在另一种实施方式中，设计了配体以热力学稳定和动力学惰性的方式螯合Mn(ll)，同时允许Mn(ll)与水直接相互作用。在另一种实施方式中，准备了含有六个Mn(ll)螯合剂的高分子量多聚体。高分子量导致分子在溶液中翻滚速度较慢，可以强烈增强Mn(ll)的弛豫率。
• ANTICANCER BENZOPYRAZINES VIA THE INHIBITION OF FGFR KINASES
  申请人：Astex Therapeutics Ltd.

  公开号：EP2776408B1

  公开（公告）日：2019-11-06
• SUBSTITUTUED QUINOXALINES AS FGFR KINASE INHIBITORS
  申请人：ASTEX THERAPEUTICS LIMITED

  公开号：US20160220564A1

  公开（公告）日：2016-08-04

  The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.